The place of eluxadoline in the management of irritable bowel syndrome with diarrhea
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by abdominal pain associated with defecation with altered stool frequency or stool form. The global prevalence of IBS ranges from 10% to 15% and total healthcare cost attributable to IBS is significant. Amo...
Main Authors: | Sherry Levio, Brooks D. Cash |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2017-09-01
|
Series: | Therapeutic Advances in Gastroenterology |
Online Access: | https://doi.org/10.1177/1756283X17721152 |
Similar Items
-
Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
by: Özdener AE, et al.
Published: (2017-09-01) -
Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea
by: Fragkos KC
Published: (2017-09-01) -
Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome: The SEPD perspective
by: Isabel Vera, et al. -
Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
by: Sobolewska-Włodarczyk A, et al.
Published: (2016-05-01) -
Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives
by: Liu R, et al.
Published: (2020-04-01)